South Sudan

Reimbursed Care Access

South Sudan does not have a formal, publicly documented national program to reimburse or broadly authorize psychedelic-assisted therapies. Ketamine is used in clinical practice as an essential anaesthetic agent, but novel psychedelic medicines (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X, and regulated esketamine products) have no evidence of national approval or reimbursement pathways and would only be accessible through approved research or exceptional importation/clinical‑trial arrangements.